Targeted Integrative Research in Drug Abuse and Hiv/Aids in Pregnancy

The summary for the Targeted Integrative Research in Drug Abuse and Hiv/Aids in Pregnancy grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Targeted Integrative Research in Drug Abuse and Hiv/Aids in Pregnancy: The National Institute on Drug Abuse (NIDA) invites targeted integrative research on epidemiological, prevention, and treatment service approaches that focus on drug abuse, HIV/AIDS and other medical consequences of drug abuse, specifically relevant to pregnant women and females of childbearing age. Pregnancy is a clinical and psychosocial phenomenon that presents public health, clinical care and drug treatment services with challenges for effective drug abuse prevention and treatment services. Pregnancy also poses challenges to the overall health care, including therapies for HIV/AIDS and other medical consequences of drug abuse. Research and clinical experience have given rise to a burgeoning knowledge base about important gender differences in addiction treatment for females. However, among drug abusing pregnant females of childbearing age, patterns of drug use and effects of use from various drugs have not been adequately characterized or addressed. This is particularly true of emerging and re-emerging drugs of abuse such as ecstasy and methamphetamine. Substance using females who are pregnant often have inadequate or no prenatal care, have greater infant morbidity and mortality in the postnatal period, and significant deficiencies in child health care utilization. In addition the new mother is likely to have significantly lower levels of maternal postpartum visits, primary care visits, contraceptive use and, most importantly, exposure to prevention intervention strategies. Studies are sought that target pregnant and postpartum drug-using females as they move through the health care and drug abuse services continuum, and on overall health outcomes specific to this population. A key focus of these studies with respect to this population is integration and application of knowledge and models of care that can blend for improved outcomes targeting drug abuse (consequences, epidemiology, prevention intervention and treatment approaches) and clinical care (therapeutics, diagnostic tools). Specifically, NIDA seeks innovative research that targets, integrates and informs scientific knowledge on unique aspects of clinical care, prevention interventions, and drug abuse treatment for drug-using pregnant females and females of childbearing age. Applicants are encouraged to compare models of care addressing certain of the many factors involving this population, such as medical, behavioral, social and service system issues. Results of these studies are expected to inform the development and design of models of care for pregnant females and females of childbearing age that blend significant components to create optimal outcomes. Studies could for example investigate integrative strategies for intervention, treatment, prevention with clinical care and pre- or post-natal service approaches that best target this population over the health care, drug abuse and behavioral risk continuum.
Federal Grant Title: Targeted Integrative Research in Drug Abuse and Hiv/Aids in Pregnancy
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-04-010
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Mar 17, 2004
Posted Date: Dec 30, 2003
Creation Date: Apr 16, 2004
Archive Date: Apr 16, 2004
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants
Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...
Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...
Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...
Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - C...
Mechanistic Studies on Social Behavior in Substance Use Disorder (R01 Clinical Trials Not ...
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allow...
Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...
Developmental AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optio...
AIDS Research Center on Mental Health and HIV/AIDS (P30 Clinical Trial Optional)
NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2024 FederalGrants.com